View Single Post
  #1  
Old Fri Dec 10, 2010, 05:14 PM
akita akita is offline
Member
 
Join Date: Nov 2010
Posts: 110
ASH 2010 Hematologic Responses in MDS Patients - Deferasirox/Exjade

Thanks to Birgittas Link to the abstracts of the ASH 2010 i found a lot of interesting abstracts for "chelation". Maybe is not every abstract interesting for everybody.. Regards, Margarete

---
http://ash.confex.com/ash/2010/webpr...aper28313.html

2912 Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria *

Citation: "Improvements in hematologic parameters and/or reductions in transfusion requirements have been associated with iron chelation therapy in transfusion-dependent patients with MDS; however, data has been limited to case reports/small studies"

Now there was a bigger study conducted where 341 iron-overloaded MDS-Patients were enrolled. They were treated with deferasirox.

Citation: "During deferasirox treatment, erythroid responses were observed in 22.6% (63/279) of patients. Median time to response was 113.0 days. Of these erythroid responses, a transfusion reduction-only response with maintenance of Hb level was observed in 10.8% (n=30) of patients, Hb improvement-only response in 10% (n=28) of patients and both transfusion and Hb response observed in 1.8% (n=5) of patients. Platelet and neutrophil responses were observed in 14.0% (n=17) of patients after a median of 169.0 days and 19.6% (n=11) of patients after a median of 226 days, respectively."

"Conclusions: This is the first large study to show that, alongside reducing iron overload, deferasirox may affect hematologic parameters in MDS patients."
__________________
Margarete, 54, living in Vienna, Austria,
MDS/AML M2, diagnosed 9/2007, then Chemos, aSZT 4/2008, chronic GVHD
Reply With Quote